Switching between anti‐tumour necrosis factors: trying to get a handle on a complex issue
AUTOR(ES)
van Vollenhoven, Ronald F
FONTE
BMJ Group
RESUMO
The question of switching is not only a question of clinical practice, but has an important scientific dimension as well See linked article, p 893
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1955116Documentos Relacionados
- Optic neuritis occurring with anti‐tumour necrosis factor α therapy
- Anti‐tumour necrosis factor α therapy in patients with impaired renal function
- Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours
- Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti‐tumour necrosis factor treatment
- Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon.